METHODS

Study Design
This was a retrospective, longitudinal, cohort study. The cohort consisted of patients registered at MSKCC with ≥1 visit(s) between January 1, 1992, and December 31, 2012. Unique patient-visits (UPV) (inpatient or outpatient) per calendar year, age, and cancer type were obtained from hospital databases. Each patient was counted once per calendar year. Patients with multiple visits during >1 calendar year were counted once per year. Three periods were examined: "before PCV7" (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) , "after PCV7" (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) and "after PCV13" (2011) (2012) .
For IPD cases, demographic and clinical characteristics including vaccination status and treatment with chemotherapeutic agents (including investigational agents and excluding hormonal therapy) within 1 month prior to IPD diagnosis were extracted from medical records.
The study was reviewed and approved by the MSKCC Institutional Review Board and was granted a waiver of authorization.
Definitions
IPD was defined as a positive culture of Streptococcus pneumoniae from a sterile site including blood, cerebrospinal fluid, pleural fluid, or synovial fluid.
Cancer types were categorized as hematologic malignancies or solid tumors based on the Surveillance, Epidemiology, and End Results Program (SEER) cancer subcategories published by the National Cancer Institute (Supplementary methods) [16, 17] . "Noncancer" included patients not meeting SEER criteria for hematologic malignancies or solid tumors. Patients with myelodysplastic syndrome, benign hematologic malignancies (such as aplastic anemia, Waldenström's macroglobulinemia, or congenital neutropenia), rare inherited disorders (such as Shwachman-Diamond syndrome, or chronic granulomatous disease), or patients with human immunodeficiency virus were categorized as "noncancer. " Patients without cancer or patients cured of cancer at the year of the visit were also included in this group.
Patients <15 years were considered "children, " and ≥15 years were "adults. " Children 0-4 years were referred to as "vaccinees, " and patients ≥5 years were "non-vaccinees. "
Microbiology
Bacterial cultures and indentification of S. pneumoniae were performed by the Clinical Microbiology Laboratory at MSKCC using standard methods [18] .
Pneumococcus serotyping was routinely performed by the Clinical Microbiology Laboratory at the New York Presbyterian Hospital until 2000. After 2000, routine serotyping was not done; instead, serotyping for selected IPD isolates was performed by the New York State Department of Health (Albany).
Pneumococcal Vaccination
Pneumococcal vaccine doses dispensed at MSKCC were obtained from the pharmacy database and reported for PPV23, PCV7, and PCV13. Pneumococcal vaccination administration outside MSKCC was not captured.
Statistical Analyses
IPD Incidence was calculated as IPD cases per 1,000 unique patient visits per year (UPV). IPD incidence was reported by cancer type (hematologic malignancies, solid tumors or non-cancer) and by age group for children (<1, 1-4, 5-14 years) and adults (15-64 and ≥65 years). A χ 2 test was used to compare IPD incidence between study periods. Applied approximation for χ 2 percentiles was used to calculate 95% confidence intervals (CI) [15] . Statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC). A 2-tailed P value ≤ .05 was considered statistically significant.
RESULTS
Invasive Pneumococcal Disease Incidence by Study Period
During the 20-year period, there were 343 IPD cases and 1.5 × 10 6 unique patient-visits (UPV). "Before PCV7" comprised 165 IPD cases and 3.9x10 5 UPV. "After PCV7" comprised 155 IPD cases, and 9.3 × 10 5 UPV and "after PCV13" comprised 23 IPD cases and 2.1 × 10 5 UPV. IPD incidence was 0.43, 0.17, and 0.11 "before PCV7, " "after PCV7, " and "after PCV13, " respectively ( Figure 1 ). IPD incidence was lower "after PCV7" Figure 1 . Overall IPD incidence by study period: "before PCV7," "after PCV7," and "after PCV13." IPD incidence was compared with the immediately preceding period. The IPD incidence was lower "after PCV7" (P < .001) and "after PCV 13" (P = .04). Unique patient-visits per period: "before PCV7," 3.9 × 10 5 ; "after PCV7," 9.3 × 10 5 and "after PCV13," 2.1 × 10
5
. Abbreviations: CI, confidence interval; IPD, invasive pneumococcal disease; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine. compared with "before PCV7" (P < .001), and IPD incidence was lower "after PCV13" compared with "after PCV7" (P = .04). Table 1 shows IPD incidence by age and cancer type. Less than 10% of total IPD cases occurred in age group 0-4 years (vaccinees). In patients 0-4 years, there was a 79% decrease in IPD "after PCV7" from 11.2 to 2.38 (P < .001).
IPD incidence in patients with hematologic malignancies was approximately 7-fold higher compared to patients with solid tumors. "After PCV7" there was a 64% decrease in IPD incidence in patients with hematologic malignancies (2.55 vs 0.92, P < .001) and a 49% decrease in patients with solid tumors (0.36 vs 0.18, P < .001). Patients with multiple myeloma had the highest IPD incidence (8.76, 2.25, and 1.39 for "before PCV7," "after PCV7," and "after PCV 13," respectively).
Compared to "after PCV7" the decline in IPD "after PCV 13" was not significant in patients with hematologic malignancies (0.92 vs 0.5 respectively, P = .074) or solid tumors (0.18 vs 0.11 respectively, P = .064).
The proportional decrease in IPD incidence "after PCV7" was more pronounced in the high-risk patients: For example, IPD declined by 74% in patients with multiple myeloma compared with 48% in patients with solid tumors (excluding head and neck). Figure 2 , upper panel, shows IPD incidence in children with hematologic malignancies. IPD declined by 44% in children 1-4 years "after PCV7" (P = NS). There were no IPD cases "after PCV13. " IPD declined in children 5-14 years "after PCV7" (7.13 vs 3.06, P = .05). Figure 2 , lower panel, shows IPD incidence in children with solid tumors. The only significant decline was in the age group 1-4 years "after PCV7. " Figure 3 , upper panel, shows IPD incidence for adults with hematologic malignancies. IPD declined "after PCV7" in patients 15-64 years (1.82 vs 0.78, P < .001) and ≥65 years (2.78 vs 0.82, P < .001). There was a numerical, nonsignificant decline in IPD "after PCV13" in patients aged 15-64 (0.78 vs 0.5, P = .32) and in those ≥65 (0.82 vs 0.36, P = .23). Figure 3 (lower panel) shows IPD incidence in adults with solid tumors. IPD declined "after PCV7" in patients aged 15-64 (0.26 vs 0.18, P = .02) and in those ≥65 (0.32 vs 0.13, P < .001). IPD declined "after PCV13" in patients aged 15-64 (0.18 vs 0.05, P = .009). Table 1 . IPD incidence "before PCV7," "after PCV7" and "after PCV13" In children aged 1-4 years, IPD decreased by 44% "after PCV7" (P = NS). There were no IPD cases "after PCV13." In children aged 5-14 years, IPD incidence was lower "after PCV7" (P = .05). Lower panel: IPD incidence in children with solid tumors: In children aged 1-4, IPD incidence declined "after PCV7" (P < .001). Abbreviation: IPD, invasive pneumococcal disease; CI, confidence interval; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine. In patients aged 15-64 and ≥65 years, IPD incidence declined "after PCV7." Lower panel: IPD incidence in adults with solid tumors: In patients aged 15-64 and ≥65 years, IPD incidence declined "after PCV7." The decline "after PCV13" was significant for patients 15-64 (P = .009). Abbreviation: IPD, invasive pneumococcal disease; CI, confidence interval; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
Characteristics of Invasive Pneumococcal Disease Cases
Of 343 IPD cases, 165 occurred "before PCV7," 155 "after PCV7, " and 23 "after PCV13. " Demographic and clinical characteristics were similar across the 3 periods ( Table 2) . The most common IPD type was bacteremia. Patients with hematologic malignancies comprised >30% of all IPD cases. Patients 0-4 years compromised 13.3% of all IPD cases "before PCV7" compared with 5.2% and 8.7% "after PCV7" and "after PCV13, " respectively. Rates of pneumococcal vaccination at MSKCC prior to IPD diagnosis ranged from 1.8% to 4.3% during the study.
Pneumococcal Serotypes "before 7-valent Pneumococcal Conjugate Vaccine"
Routine serotyping was performed "before PCV7" only (Table 3) . Serogroup 6 compromised 20.6% of all isolates followed by serogroup 23 (15.2%). "Before PCV7, " 67% of IPD serotypes were included in PCV7. Serotypes were available for only 3 IPD cases "after PCV7" (serotypes 15A, 19A, 22F) and for 1 IPD case "after PCV13" (serotype 15A).
Three IPD cases "before PCV7" had documented vaccination with PPV23 prior to IPD diagnosis. IPD was caused by PPV23 serogroups (serogroup 6 in 1 patient and serogroup 15 in 2 patients). IPD serotype was available for 1 case "after PCV7" (serotype 22F, not included in PCV7).
Trends in the Annual Incidence of Invasive Pneumococcal Disease
We examined trends in the annual incidence of IPD by age group and cancer type. Overall, there was an abrupt decline in IPD coinciding with the implementation of routine childhood immunization with PCV7 in 2000. Figure 4 shows annual trends in children. In children with hematologic malignancies, IPD declined abruptly in 2000 ( Figure 4A ). Similarly in children with solid tumors, IPD declined abruptly in 2000 ( Figure 4B ). During the study period, the number of UPV per year for children with hematologic malignancies remained constant while UPV for children with solid tumors showed a modest annual growth (Supplement, Figure 1A and 1B). Figure 5A and 5B shows annual trends in adults. In adults with hematologic malignancies, IPD declined abruptly in 2000 ( Figure 5A ). Adults with solid tumors had 10-fold lower IPD incidence compared to adults with hematologic malignancies ( Figure 5B ). In adults with solid tumors, there was a trend for lower annual IPD incidence "after PCV7. " There was a substantial, annual growth in UPV for patients with solid tumors "after PCV7" (Supplement, Figure 2B ).
Pneumococcal Vaccine Utilization
The ratio of vaccine doses/UPV ranged from 2% to 4% during the study periods (Supplement, Table 1 ). Only vaccines dispensed at MSKCC were captured. Vaccines administered by primary care providers were not captured.
DISCUSSION
We analyzed the epidemiology of IPD at a major cancer center over a 20-year period. Of 343 IPD cases identified, >90% occurred in adults. Our key findings are: (i) IPD incidence decreased in all ages and cancer types after routine childhood pneumococcal immunization with PCV7 (2001-2010) compared to "before PCV7" (1992-2000) (P < .001); (ii) IPD incidence declined abruptly in children and adults with hematologic malignancies in 2000 and remained stable through 2010.
During the study, changes in patient demographics and/ or health care delivery as well as advances in cancer and supportive care could have had a differential impact on the incidence of IPD across patient groups. These variables could not be adequately controlled in a retrospective, longitudinal study. We showed similar trends in the incidence of IPD across cancer types and age groups. Patients 0-4 years (vaccinees) had highest IPD incidence and a profound decline in IPD (79%) "after PCV7. " Importantly we also observed significant declines in non-vaccinees. Adults with hematologic malignancies had a 64% decline in IPD incidence "after PCV7. " Our findings are in agreement with trends in the general adult population [4, [11] [12] [13] . A decrease in the nasal carriage of PCV7 serotypes in vaccinated children may partially account for the decline of IPD in nonvaccinees via herd immunity [19] [20] [21] [22] . An increase in the nasal carriage of non-vaccine serotypes has been observed after PCV7 [23] . Since the introduction of PCV13 in the United States, IPD caused by PCV13/non-PCV7 serotypes has declined by 93% [15] . The IPD rate in adults ≥ 65 years reached a plateau in 2015 [24] suggesting that IPD by non-PCV13 serotypes may be replacing PCV13 serotypes.
The indirect protective effect of PCV7 in cancer patients is not well-defined [25] . This is especially relevant in view of reports of increased prevalence of non-PCV7 serotypes in recent studies [26, 27] . In the Midwestern United States, after 2010, the rate of IPD due to PCV13 serotypes was not significantly lower compared with the rate prior to the introduction of PCV13 [28] . In our cohort, the decline of IPD in non-vaccinees (≥5 years) with hematologic malignancies suggests an indirect effect of routine childhood immunization with PCV7. While there was a numerical decline "after PCV13, " a longer period of observation is required to ascertain the potential impact of PCV13 in cancer patients.
We observed an abrupt decline in the incidence of IPD in 2000, coinciding with the introduction of PCV7. This stepdown decline in 2000 was noted in children aged 5-14 and in adults with hematologic malignancies. Whitney et al noted a significant decline in IPD rates in children in 2000; however, the largest drop did not occur until 2001 [12] . In our cohort, the incidence dropped in 2000 and remained relatively stable through 2010. A similar observation was reported in Spain after the introduction PCV7 [27] . Our study has several limitations. First, we may have underestimated the IPD incidence because we captured IPD cases diagnosed only at MSKCC and not at outside hospitals. In general, patients treated with hematologic malignancies at MSKCC use MSKCC as their primary institution. Assuming that the proportion of IPD treated outside MSKCC remained constant over time, this would not have had an impact on the trends of IPD. Second, the number of unique patient visits (UPV) "after PCV7" (2000-2010) doubled compared with "before PCV7, " mainly due to an increase in UPV of adults with solid tumors at our center. The increase of UPV may have affected the calculated incidence of IPD in this group. Since approximately 2000, there was a gradual expansion of MSKCC via the opening of "regional centers" targeting adults with solid tumors. The IPD incidence in adults with solid tumors was very low even "before PCV7. " To our knowledge there were no major changes in the delivery of care of pediatric patients or adults with hematologic malignancies at our Institution. Those 2 groups had the highest IPD incidence. The increase in UPV was minimal among children and modest among adults with hematologic malignancies. The abrupt drop in IPD incidence for all patients with hematologic malignancies in 2000 was not due to an abrupt increase in UPV in 2000.
A third limitation is the lack of detailed pneumococcal immunization records. We used the aggregate number of vaccine doses dispensed at MSKCC as a rough estimate of vaccination rates. We do not know the reasons for not vaccinating patients for whom the vaccine was indicated. The opportunity for pneumococcal vaccination is often missed during health encounters [29] . Alternatively, MSKCC physicians may have deemed that patients would not respond to pneumococcal vaccination due to their underlying disease or therapy [30, 31] . Preliminary data suggest that patients with solid tumors may respond to pneumococcal vaccination [32, 33] . PCV7 was shown to be more immunogenic than PPV23 in patients with hematologic malignancies and recipients of HCT [34, 35] . In a study from our Institution, the response rates to selected serotypes of PCV7 and/or PCV13 ranged from 60% to 88% and 45% to 50% in revaccinated children and adults who were respectively deemed suitable for revaccination after allogeneic HCT [36, 37] . Since 2000, the Advisory Committee on Immunization Practices (ACIP) has issued several updates on the indications and regimens of pneumococcal immunization in patients with underlying medical conditions [38, 39] .
As IPD serotypes "after PCV7" were not available for our patients, we do not know if IPD cases "after PCV7" were caused by serotypes included in PCV7 or in PCV13. We plan to implement routine serotyping of IPD isolates as part of IPD surveillance moving forward.
Acknowledging these limitations, this is a large study reporting IPD rates in cancer patients after the introduction of PCV7. Prospective studies are needed to assess the impact of PCV13 especially in areas with high compliance with routine childhood immunizations, including PCV13.
In conclusion, IPD incidence declined "after PCV7" in children 0-4 years (vaccinees) and in patients ≥5 years (nonvaccinees) with hematologic malignancies. The decline in adults with hematologic malignancies suggests an indirect effect of routine childhood immunization with PCV7. Continued surveillance is warranted to characterize the burden of IPD in the era of PCV13 and optimize preventive strategies in highly immunocompromised patients.
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